Latest News on SF

Financial News Based On Company


Advertisement
Advertisement

Stifel Financial Corp. (SF-PB) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/SF-PB/
This article provides a detailed overview of Stifel Financial Corp. (SF-PB) stock, including its current price, dividend information, key financial metrics, and company profile. It also presents performance data compared to the S&P 500 and insights into earnings trends and valuation measures. The company is described as a bank holding company offering retail and institutional wealth management and investment banking services globally.

Stifel reiterates Buy on Nvidia stock, keeps $205 price target

https://www.investing.com/news/analyst-ratings/stifel-reiterates-buy-on-nvidia-stock-keeps-205-price-target-93CH-5034975
Stifel maintained its Buy rating on Nvidia (NASDAQ:NVDA) stock and kept its $205 price target, citing strong financial performance and guidance. Nvidia reported robust third-quarter fiscal 2027 revenue and raised its fiscal 2028 growth outlook, leading to positive analyst sentiment despite some concerns about leadership transition and regulatory impacts.

Stifel raises VF Corp. price target to $19 on cost control confidence

https://uk.investing.com/news/stock-market-news/stifel-raises-vf-corp-price-target-to-19-on-cost-control-confidence-93CH-4988140
Stifel has increased its price target for VF Corp. (NYSE:VFC) shares to $19 from $17, maintaining a Hold rating, due to increased confidence in the company's cost control measures. VF Corp.'s fiscal 2028 guidance projects $9.8 billion in revenue and $850 million in adjusted operating income, exceeding Stifel's previous profit estimate. The updated target also considers the company's consistent brand commentary and focus on long-term growth and Vans brand stabilization.

Stifel executive charged with DWI after fatal ATV crash

https://www.bizjournals.com/stlouis/news/2026/11/17/stifel-executive-charged-dwi-after-fatal-atv-crash.html
A senior executive at Stifel Financial Corp. has been charged with driving while intoxicated following a fatal ATV accident in Dent County. The crash resulted in the death of a 57-year-old passenger. This article was published on November 17, 2026.

Best Buy (NYSE:BBY) Coverage Initiated by Analysts at Stifel Nicolaus

https://www.marketbeat.com/instant-alerts/analyst-best-buy-nyse-bby-coverage-initiated-by-analysts-at-stifel-nicolaus-2026-11-17/
Stifel Nicolaus has initiated coverage on Best Buy (NYSE:BBY) with a "Hold" rating and a $100 price target, suggesting a slight downside from its current price. This aligns with the overall analyst sentiment, as Best Buy holds an average "Hold" rating and a consensus price target of $88.59 from 23 analysts. The company recently surpassed quarterly earnings estimates, reporting $1.47 EPS against a $1.39 consensus, and revenue of $9.78 billion, exceeding expectations with a 3.6% year-over-year increase.
Advertisement

Stifel cuts Bally’s stock price target on earnings misses

https://www.investing.com/news/analyst-ratings/stifel-cuts-ballys-stock-price-target-on-earnings-misses-93CH-5032228
Stifel has reduced its price target for Bally's Corp (NYSE:BALY) to $12 from $13, maintaining a Hold rating, following the company's 11th consecutive quarterly earnings miss. Bally's reported adjusted EBITDAR 5% below consensus, largely due to underperformance in its casino and resort segment and persistent "going concern" risk despite securing pre-construction financing. The company faces significant debt and negative free cash flow, with investor focus now on future project openings and financing catalysts.

Stifel cuts HMH stock price target on Middle East headwinds By Investing.com

https://ca.investing.com/news/stock-market-news/stifel-cuts-hmh-stock-price-target-on-middle-east-headwinds-93CH-4960091
Stifel has lowered its price target for HMH Holding Inc (NASDAQ:HMH) shares from $28 to $25, while maintaining a Buy rating, following the company's third-quarter results. The adjustment is due to revenue and adjusted EBITDA missing projections, primarily impacted by continued headwinds in the Middle East, leading HMH to reduce its 2026 EBITDA guidance. Despite these near-term challenges, Stifel and InvestingPro analysis suggest the stock is undervalued and anticipate higher profitability in 2027-28 driven by rising deepwater activity.

Victorian Plumbing tipped for growth as Stifel highlights Trade opportunity

https://uk.finance.yahoo.com/news/victorian-plumbing-tipped-growth-stifel-111500522.html
Stifel has initiated coverage on Victorian Plumbing Group PLC with a 'buy' rating and a 110p price target, citing attractive medium-term growth potential despite a challenging market. The broker highlights the company's Trade operation, Tiles & Flooring business, and the new MFI homewares venture as key drivers for future revenue and profit growth. Stifel forecasts significant increases in group revenue and adjusted profit before tax, supported by strategic investments and expansion.

Stifel cuts Proficient Auto Logistics stock price target on margin pressures

https://www.investing.com/news/analyst-ratings/stifel-cuts-proficient-auto-logistics-stock-price-target-on-margin-pressures-93CH-5025119
Stifel has reduced its price target for Proficient Auto Logistics (NASDAQ:PAL) from $10.00 to $9.00, while maintaining a Buy rating. This adjustment follows the company's Q3 2026 adjusted EPS miss, driven by margin compression from rising fuel costs. Despite current challenges and a significant year-to-date stock decline, analysts predict profitability this year and an undervalued stock position.

Stifel cuts EyePoint stock price target on trial setbacks

https://www.investing.com/news/analyst-ratings/stifel-cuts-eyepoint-stock-price-target-on-trial-setbacks-93CH-5025313
Stifel has lowered its price target for EyePoint Inc. (NASDAQ:EYPT) from $6.00 to $5.00, while maintaining a Buy rating, following setbacks in clinical trials for wet age-related macular degeneration. The company is now focusing on its Duravyu treatment for diabetic macular edema, with Phase 3 results expected in late Q4 2027. EyePoint has also reduced its workforce by 53% and terminated early follow-up studies to conserve its $118 million cash reserves.
Advertisement

YETI (NYSE:YETI) Stock Price Target Lowered at Stifel Nicolaus

https://www.marketbeat.com/instant-alerts/analyst-yeti-nyse-yeti-stock-price-target-lowered-at-stifel-nicolaus-2026-11-13/
Stifel Nicolaus has lowered its price target for YETI (NYSE:YETI) from $50 to $48, while maintaining a "buy" rating, indicating a potential upside of 25.23%. This adjustment comes amidst mixed analyst sentiment, with Piper Sandler downgrading YETI to "neutral" and cutting its target to $39, although the overall consensus remains a "Moderate Buy" with a $53.33 target. YETI recently reported third-quarter EPS of $0.91, surpassing estimates, but revenue of $517.93 million fell short of expectations despite a 4.4% year-over-year growth.

Spyglass Pharma (NASDAQ:SGP) Stock Price Target Raised at Stifel Nicolaus

https://www.marketbeat.com/instant-alerts/analyst-spyglass-pharma-nasdaq-sgp-stock-price-target-raised-at-stifel-nicolaus-2026-11-13/
Stifel Nicolaus has increased its price target for Spyglass Pharma (NASDAQ:SGP) from $42.00 to $44.00, reiterating a "buy" rating with a potential upside of 32.05%. This follows other analyst adjustments, resulting in a "Moderate Buy" consensus rating and an average target price of $45.33 for SGP, despite the company missing its recent quarterly EPS estimate.

Stifel Financial (SF) lists 7,898 holdings entries totaling $121B.

https://www.stocktitan.net/sec-filings/SF/13f-hr-stifel-financial-corp-sec-filing-4aa5a031e063.html
Stifel Financial Corp (SF) has reported 7,898 Form 13F information-table entries with a total value of $120,920,030,196. The report includes holdings from six other institutional investment managers. The filing was made available on EDGAR on November 12, 2026, at 02:59 PM EST.

SF: SEC Form 13F-HR filed by Stifel Financial Corporation

https://www.quantisnow.com/insight/sec-form-13f-hr-filed-by-stifel-financial-corporation-6787401
Stifel Financial Corp. has filed its quarterly Form 13F holdings report for the quarter ended September 30, 2026, revealing 7,898 positions with a combined reported value of approximately $120.9 billion. This filing covers holdings across six included managers, providing insight into the securities the firm holds for its clients. The report details key figures such as the number of entries, total value, and the affiliated firms included.

Syndax at Stifel 2026 Healthcare Conference: growth and pipeline push

https://www.investing.com/news/transcripts/syndax-at-stifel-2026-healthcare-conference-growth-and-pipeline-push-93CH-5022422
Syndax Pharmaceuticals presented at the Stifel 2026 Healthcare Conference, highlighting strong commercial growth for its drugs Revuforj and Niktimvo, with increased patient starts and improved margins. The company also discussed its pipeline, including two Phase III frontline AML studies and new EGFR and next-generation menin inhibitors, while addressing competitive positioning and future growth strategies.
Advertisement

Stifel cuts EVgo stock rating on go-private bid, slower EV growth

https://www.investing.com/news/analyst-ratings/stifel-cuts-evgo-stock-rating-on-goprivate-bid-slower-ev-growth-93CH-5020339
Stifel downgraded EVgo, Inc. (NASDAQ:EVGO) from Buy to Hold and reduced its price target to $2.50 from $6.00 due to a go-private acquisition proposal and slower-than-expected electric vehicle adoption. Despite third-quarter 2026 revenue being close to estimates, the company remains unprofitable, and management lowered 2026 guidance. This follows similar downgrades from RBC Capital and Roth/MKM, also citing concerns about the take-private offer from LS Power and insufficient cost reductions.

Stifel raises Martin Marietta stock price target on pricing outlook

https://www.investing.com/news/analyst-ratings/stifel-raises-martin-marietta-stock-price-target-on-pricing-outlook-93CH-5018743
Stifel has increased its price target for Martin Marietta Materials (NYSE:MLM) to $653 from $629, maintaining a Buy rating, citing a positive pricing outlook for 2027. This adjustment follows the company's third-quarter 2026 revenue exceeding expectations, driven by acquisitions and strong performance in its Specialties segment, despite a slight decline in organic volume. Martin Marietta also raised its guidance after the Lhoist acquisition and expects mid-to-high single-digit pricing growth next year, bolstered by an inflationary environment and network optimization benefits.

Denali Therapeutics at Stifel 2026 Healthcare Conference: launch gains

https://www.investing.com/news/transcripts/denali-therapeutics-at-stifel-2026-healthcare-conference-launch-gains-93CH-5019360
Denali Therapeutics presented at the Stifel 2026 Healthcare Conference, highlighting a strong launch for its Hunter's disease drug, AVLAYAH, which generated $7.8 million in its second quarter after launch and is expected to reach $30 million to $32 million in the fourth quarter. The company has a robust cash reserve of $1.01 billion and a promising pipeline with several data readouts anticipated in 2027 and 2028 for programs in Sanfilippo syndrome, Pompe disease, Alzheimer's, and progranulin, leveraging its Transport Vehicle platform for improved drug delivery.

AtriCure at Stifel 2026 Healthcare Conference: growth stays broad

https://www.investing.com/news/transcripts/atricure-at-stifel-2026-healthcare-conference-growth-stays-broad-93CH-5019724
AtriCure reported strong Q3 2026 revenue growth of 15%, driven by a 33% increase in pain management, and provided a conservative Q4 revenue guidance of $606 million to $610 million. The company is tracking ahead of its 2028 adjusted EBITDA margin target and expects significant catalysts in 2027 from the BoxX trial readout and the rollout of the STS quality metric for atrial fibrillation care. Management emphasized internal investment in R&D and sales force expansion, along with new product development in its left atrial appendage portfolio.

Sight Sciences at Stifel 2026 Healthcare Conference: TearCare gains ground

https://www.investing.com/news/transcripts/sight-sciences-at-stifel-2026-healthcare-conference-tearcare-gains-ground-93CH-5019485
Sight Sciences presented at the Stifel 2026 Healthcare Conference, highlighting significant momentum in its dry eye treatment, TearCare, and its glaucoma business. TearCare is gaining strong reimbursement support and customer adoption, with management anticipating substantial long-term market opportunity well beyond prior estimates. The company also announced the Q4 2026 launch of OMNI Ultra for glaucoma, expecting it to provide a modest lift this quarter and more significant contributions next year, all while maintaining controlled spending growth.
Advertisement

Stifel CEO: Using Anthropic's AI tools made us realize we need more positions

https://www.foxbusiness.com/video/6408204231112
Stifel CEO Ron Kruszewski discussed the integration of Anthropic's Claude AI into his firm's financial advisor workflow, revealing that the use of these AI tools highlighted a need for more positions within the company. Kruszewski also commented on Anthropic's amended S-1 filing to offer 825 million shares ahead of its Nasdaq debut. The discussion took place on 'The Claman Countdown'.

Stifel is working with Claude's maker to rethink the dashboard advisers use to serve clients.

https://www.stocktitan.net/news/SF/stifel-working-with-anthropic-to-reimagine-its-dashboard-platform-hs2i4zdxgrle.html
Stifel Financial (NYSE: SF) is collaborating with Anthropic, the creator of Claude, to modernize its Dashboard platform, which financial advisors utilize for practice management and client service. This initiative aims to integrate Anthropic's AI capabilities, including Claude, Claude Code, and Claude Design, with Stifel's understanding of advisor workflows, while maintaining the platform's existing functionality. The partnership was announced at Stifel's Blueprint 2026 innovation conference and underscores Stifel's commitment to enhancing advisor technology and client service.

Protalix at Stifel 2026 Healthcare Conference: growth and pipeline buildout

https://www.investing.com/news/transcripts/protalix-at-stifel-2026-healthcare-conference-growth-and-pipeline-buildout-93CH-5017319
Protalix (PLX) presented at the Stifel 2026 Healthcare Conference, highlighting strong commercial sales, a growing pipeline, and a healthier cash position. The company reported year-to-date revenue of $75.6 million through Q3 2024 and provided 2026 revenue guidance of $78 million to $83 million. A key catalyst is the upcoming data from PRX-115, its Phase II gout program, with enrollment expected to complete in Q1 2025 and data readout within a year.

Stifel taps Anthropic to overhaul technology platform for financial advisers

https://www.bizjournals.com/stlouis/news/2026/11/10/stifel-partners-with-anthropic-overhaul-financial.html?page=all
Stifel Financial is partnering with Anthropic to enhance its technology platform for financial advisers. This project aims to integrate Anthropic's AI technology with Stifel's existing knowledge of adviser workflows, aligning with Stifel's broader strategy to incorporate AI across its various businesses.

Stifel Financial Corp. Partners with Anthropic to Reimagine Advisor Dashboard Platform

https://www.quiverquant.com/news/Stifel+Financial+Corp.+Partners+with+Anthropic+to+Reimagine+Advisor+Dashboard+Platform
Stifel Financial Corp. has announced a partnership with Anthropic to modernize and enhance its Dashboard platform, which is crucial for its financial advisors. Revealed at Stifel's Blueprint 2026 conference, this collaboration will integrate Anthropic's AI technologies, including Claude, to improve the advisor workspace while retaining the platform's user-friendly design. Stifel's CEO emphasized the company's commitment to investing in technology that supports advisors and enhances client service.
Advertisement

Outset Medical at Stifel 2026 healthcare conference: policy tailwind builds

https://www.investing.com/news/transcripts/outset-medical-at-stifel-2026-healthcare-conference-policy-tailwind-builds-93CH-5016601
Outset Medical (OM) outlined its business growth and long-term profit goals at the Stifel 2026 Healthcare Conference, highlighting strong Q3 2024 results, a favorable federal kidney-care policy, and a growing recurring-revenue base. Despite keeping its 2026 revenue outlook conservative, the company anticipates significant growth in the latter half of 2024 and is strategically preparing for a major next-generation Tablo release, targeting 50% gross margin over the next three to five years. The company's strategy focuses on expanding within existing customer accounts, refreshing older consoles, and leveraging EMR integration, while a new sales leadership aims to deepen engagement with current clients rather than solely pursuing new acquisitions.

Oxford Nanopore at Stifel 2026 Healthcare Conference: sharper focus, steady growth

https://www.investing.com/news/transcripts/oxford-nanopore-at-stifel-2026-healthcare-conference-sharper-focus-steady-growth-93CH-5016595
Oxford Nanopore Technologies presented at the Stifel 2026 Healthcare Conference, outlining a refined growth strategy centered on its long-read sequencing platform. The company aims for EBITDA break-even by 2027 by focusing commercial efforts on 15 priority markets, expanding gross margins, and maintaining cost discipline. Key growth areas include biopharma, clinical diagnostics, and AI-related data applications, with a notable cross-licensing deal expected to significantly contribute to future revenue.

Stifel Working with Anthropic to Reimagine Its Dashboard Platform with Claude

https://www.globenewswire.com/news-release/2026/11/10/3400059/0/en/stifel-working-with-anthropic-to-reimagine-its-dashboard-platform-with-claude.html
Stifel Financial Corp. announced its collaboration with Anthropic to enhance and reimagine its Dashboard platform, a critical tool for Stifel financial advisors. This initiative, unveiled at Blueprint 2026, aims to integrate advanced AI tools like Claude, Claude Code, and Claude Design to modernize the advisor workspace while retaining familiar functionality. Stifel's Chairman and CEO, Ronald J. Kruszewski, emphasized the company's commitment to investing in technology that supports advisors in delivering exceptional client service.

Starbucks Stocks Rise 3.74% as Stifel Resumes With Buy, $115 Target

https://www.tradingview.com/news/gurufocus:58c770cf7094b:0-starbucks-stocks-rise-3-74-as-stifel-resumes-with-buy-115-target/
Starbucks (SBUX) shares rose 3.74% after Stifel resumed coverage with a Buy rating and a $115 price target, citing an "increasingly self-funding" earnings recovery. Despite a revenue fall due to a China joint venture transition, the company reported strong global comparable sales growth and improved operating margin in Q4. However, international comparable sales remain a weak point, and the stock trades at a premium to its fiscal 2027 earnings guidance.

SpaceX Shares Climb as Stifel Reiterates Buy, Sees Opportunity in Delayed Data Centers

https://finance.biggo.com/news/17afa1ae-cd05-4698-976e-87495f8a81c3
SpaceX shares rose after Stifel reiterated a buy rating and $190 price target, suggesting that state-level permitting delays for U.S. data centers could create an opportunity for SpaceX to acquire stalled projects with existing power access. Analyst Jonathan Siegmann also highlighted $40 billion in GPU financing and the upcoming Starship Flight 15 as potential catalysts for the company, particularly in its long-term ambition for orbital computing. Investors are closely watching the Starship Flight 15, targeted for November 13, which aims for the first full recovery of an orbital system.
Advertisement

Stifel Financial (SF) Adds Capital Markets Leaders, Does It Look Fairly Valued?

https://simplywall.st/stocks/us/diversified-financials/nyse-sf/stifel-financial/news/stifel-financial-sf-adds-capital-markets-leaders-does-it-loo
Stifel Financial (SF) recently strengthened its Capital Solutions platform by hiring Adam Steinberg, Mickey Brunton, and Gavin Kolt, a move that comes amidst mixed share price performance. While the company has seen an 88.9% total shareholder return over three years, it experienced a 10.6% decline in the past year, with its stock currently at $71.35. Analysts view Stifel Financial as modestly undervalued at $80.88, driven by growth in its venture and fund banking ecosystem, but potential legal costs and financial strength issues pose risks.

CW Maintained by Stifel -- Price Target Lowered to $472

https://www.gurufocus.com/news/9185053/cw-maintained-by-stifel-price-target-lowered-to-472
Stifel has maintained a "Hold" rating on Curtiss-Wright (CW) but lowered its price target to $472 from $518, citing evolving market conditions. Despite this, GuruFocus assesses CW as 4.1% undervalued with a strong GF Score™ of 94/100, driven by high profitability and growth rankings. However, mixed signals from guru and insider transactions suggest a cautious outlook for investors.

Stifel cuts Eos Energy stock price target on bookings concerns

https://www.investing.com/news/analyst-ratings/stifel-cuts-eos-energy-stock-price-target-on-bookings-concerns-93CH-5011520
Stifel has lowered its price target for Eos Energy Enterprises (NASDAQ:EOSE) from $9.00 to $4.00, while maintaining a Buy rating, citing concerns over light bookings despite sequential improvements in gross margin. The company's stock has seen a significant decline, but its third-quarter 2026 results were consistent with prior announcements, and management narrowed revenue guidance. Although Eos Energy exceeded analyst estimates for revenue and adjusted earnings, it continues to face challenges with ongoing losses and cash burn.

A medical-device company's president, CEO and CFO will meet investors in New York.

https://www.stocktitan.net/news/PROF/profound-medical-to-participate-in-the-stifel-2026-healthcare-t9bvefk8ds86.html
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) is set to present at the Stifel 2026 Healthcare Conference on November 12, 2026, in New York City. President Richard Fabian will deliver a presentation, which will be broadcast live online. Fabian, along with CEO Arun Menawat and CFO Matthew Sobczyk, will also engage in one-on-one investor meetings during the conference.

Stifel Financial Corporation $SF Stock Position Reduced by Beverly Hills Private Wealth LLC

https://www.marketbeat.com/instant-alerts/filing-stifel-financial-corporation-sf-stock-position-reduced-by-beverly-hills-private-wealth-llc-2026-11-09/
Beverly Hills Private Wealth LLC significantly reduced its stake in Stifel Financial Corporation (NYSE:SF) by 30.2% in the third quarter, selling 16,860 shares and retaining 38,989 shares valued at approximately $2.73 million. Stifel Financial reported quarterly EPS of $1.46, exceeding analyst expectations, but revenue of $1.43 billion was slightly below estimates and down 0.2% year-over-year. Analyst sentiment remains mixed, with a consensus "Hold" rating and an average price target of $85.71, and the company recently declared a quarterly dividend of $0.34 per share.
Advertisement

Profound Medical to Participate in the Stifel 2026 Healthcare Conference

https://www.quantisnow.com/insight/profound-medical-to-participate-in-the-stifel-2026-healthcare-conference-6780278
Profound Medical Corp. announced that its President, Richard Fabian, will present at the Stifel 2026 Healthcare Conference on November 12, 2026, at 8:40 a.m. Eastern Time. The presentation will be broadcast live and archived on the company's website, providing an update for shareholders. This event is a scheduled investor event, not related to new financial or clinical results.

Profound Medical to Participate in the Stifel 2026 Healthcare Conference

https://quantisnow.com/insight/profound-medical-to-participate-in-the-stifel-2026-healthcare-conference-6780278
Profound Medical Corp. announced its participation in the Stifel 2026 Healthcare Conference, where its President, Richard Fabian, will present on November 12, 2026, at 8:40 a.m. ET. The article provides historical stock performance context for Profound Medical after previous headlines, noting a median move of 2.5% in either direction. It also offers a snapshot of recent company announcements and financial data available through Quantisnow.

Stifel upgrades Treace Medical stock on growth, profitability outlook

https://www.investing.com/news/analyst-ratings/stifel-upgrades-treace-medical-stock-on-growth-profitability-outlook-93CH-5010577
Stifel has upgraded Treace Medical Concepts Inc (NASDAQ:TMCI) to Buy from Hold, raising its price target to $6.50 from $4.50, citing expectations for stronger revenue growth and improved adjusted EBITDA profitability. The company recently reported its 12th consecutive revenue beat and its first positive adjusted EBITDA outside of seasonally strong quarters since its 2021 IPO. Despite a recent stock drop due to a cautious full-year outlook, Stifel believes innovation will drive better sales and profitability in 2027 and beyond.

Does Capital Solutions Hires Change The Bull Case For Stifel Financial Stock (SF)?

https://simplywall.st/stocks/us/diversified-financials/nyse-sf/stifel-financial/news/does-capital-solutions-hires-change-the-bull-case-for-stifel
Stifel Financial (SF) recently declared dividends on its common and preferred stock and expanded its Capital Solutions leadership team by hiring veterans in capital structure advisory, GP led secondaries, and private capital markets. This move aims to boost fee-based advisory revenue and address complex financing mandates, potentially reshaping the investment narrative around adviser-led growth. While the firm projects significant revenue and earnings growth by 2029, risks like legal cases and funding concentration remain, and some analysts offer more cautious forecasts.

Stifel raises Chatham Lodging Trust price target on business travel strength

https://www.investing.com/news/analyst-ratings/stifel-raises-chatham-lodging-trust-price-target-on-business-travel-strength-93CH-5005076
Stifel has increased its price target for Chatham Lodging Trust (NYSE:CLDT) shares to $16.50 from $15.50, maintaining a Buy rating. This adjustment reflects the strong performance in business transient travel, which accounts for approximately 75% of the company's EBITDA. The company's portfolio saw an 83% occupancy rate in Q3, the highest since 2019, driven by this momentum.
Advertisement

Stifel raises Coherent stock price target on PhotonLink deal

https://www.investing.com/news/analyst-ratings/stifel-raises-coherent-stock-price-target-on-photonlink-deal-93CH-5002702
Stifel has increased its price target on Coherent (NYSE:COHR) stock to $450 from $420, maintaining a Buy rating after the company's strong first-quarter fiscal 2027 results. Coherent reported revenues and EPS that surpassed consensus estimates and provided optimistic second-quarter guidance, alongside announcing a significant $20 billion PhotonLink agreement. Despite a recent stock decline, analysts project substantial upside potential, anticipating continued sales growth and improved gross margins.

Stifel cuts Camtek stock price target on margin pressures

https://www.investing.com/news/analyst-ratings/stifel-cuts-camtek-stock-price-target-on-margin-pressures-93CH-5001039
Stifel has lowered its price target for Camtek Ltd. (NASDAQ:CAMT) from $170 to $140, maintaining a Hold rating due to margin pressures and capacity constraints. Despite the reduction, Camtek reported third-quarter revenue and a fourth-quarter outlook consistent with prior updates, with strong order visibility into 2027, particularly in advanced packaging and AI logic applications. The stock has seen recent volatility, declining nearly 13% in the past week and 39% over six months.

Learn Why The Bull Case For Stifel Could Change Following Senior Banking Hires

https://sg.finance.yahoo.com/news/learn-why-bull-case-stifel-051459172.html
Stifel Financial (SF) has declared cash dividends on common and preferred shares and reported its Q3 2026 results, while also announcing senior hires in Capital Solutions and European investment banking. These appointments, including seasoned dealmakers, suggest a sharper focus on complex financings, GP-led secondary deals, and fintech advisory work. The article explores how these developments, along with analyst forecasts and balance sheet risks, could influence Stifel Financial's investment narrative and future performance.

Stifel cuts Revolve Group stock price target on margin pressure

https://www.investing.com/news/analyst-ratings/stifel-cuts-revolve-group-stock-price-target-on-margin-pressure-93CH-4997873
Stifel has lowered its price target for Revolve Group (NYSE:RVLV) from $33 to $31, while maintaining a Buy rating. The adjustment reflects new expenses from joint ventures and fuel surcharges, which are expected to reduce adjusted EBITDA margin for 2026, despite strong revenue growth drivers like new customer acquisition and broad category demand. Revolve Group recently reported mixed Q3 2026 results with revenue beating expectations but earnings per share falling short due to margin pressures.

Stifel (SF) Stock Looks Fully Priced After An 81% Run

https://simplywall.st/stocks/us/diversified-financials/nyse-sf/stifel-financial/news/stifel-sf-stock-looks-fully-priced-after-an-81-run
Stifel Financial (SF) has seen its stock gain 81.4% over the past three years, prompting questions about its current valuation relative to its returns on capital. The Excess Returns model suggests the stock, currently priced at $68.64, is broadly in line with its intrinsic value, with an estimated excess return of $1.29 per share. Recent developments in investment banking leadership and wealth management contribute to the discussion on whether the company's profitability justifies its current share price.
Advertisement

Stifel reiterates Buy on Diamondback Energy stock, $259 target

https://www.investing.com/news/analyst-ratings/stifel-reiterates-buy-on-diamondback-energy-stock-259-target-93CH-4995587
Stifel maintained its Buy rating and $259 price target for Diamondback Energy (NASDAQ:FANG) after the company's Q3 2026 results showed oil volume and capital expenditures met expectations, and cash flow exceeded estimates. Diamondback Energy also increased its fixed dividend by 7%, marking its ninth consecutive year of payments, and reported strong performance in its Barnett operations, which now offer competitive returns. The company plans to focus on zonal development efficiency across its expanded Barnett footprint and pursue long-term initiatives in natural gas monetization, power demand, and increased recoveries.

Stifel Financial Corporation (NYSE:SF) Declares Quarterly Dividend of $0.34

https://www.marketbeat.com/instant-alerts/dividend-stifel-financial-corporation-nyse-sf-declares-quarterly-dividend-of-034-2026-11-03/
Stifel Financial Corporation (NYSE:SF) announced a quarterly dividend of $0.34 per share, payable on December 15, 2026, to shareholders of record on December 1, 2026. This translates to an annualized dividend of $1.36 and a 2.0% yield. The company has a history of nine consecutive years of dividend increases, supported by a low payout ratio of 15.4%, and recently beat earnings estimates with $1.46 per share.

Stifel adds three managing directors to capital solutions unit By Investing.com

https://ng.investing.com/news/stock-market-news/stifel-adds-three-managing-directors-to-capital-solutions-unit-93CH-2775082
Stifel Financial Corp. (NYSE:SF) has appointed three new managing directors to its Capital Solutions platform. Adam Steinberg will head the Capital Structure Advisory Group, Mickey Brunton was named Co-Head of Eaton Partners’ GP-led Secondaries Advisory Group, and Gavin Kolt will lead the Private Capital Markets Group. These appointments aim to strengthen Stifel's investment banking capabilities with experienced professionals based in New York.

KBW Appoints Mark Tweedie as Head of European Investment Banking

https://markets.businessinsider.com/news/stocks/kbw-appoints-mark-tweedie-as-head-of-european-investment-banking-1036706434
Keefe, Bruyette & Woods, Inc. (KBW) has appointed Mark Tweedie as Managing Director and Head of Investment Banking in Europe. Tweedie, previously Head of EMEA Fintech at Citigroup, will lead KBW's European investment banking efforts, focusing on fintech. This appointment comes as KBW aims to strengthen its global financial services and fintech advisory presence.

Stifel Financial Corp. DEP RP SHS PFD Cpr declares $0.3828 dividend

https://www.tradingview.com/news/seekingalpha:6e97ac220094b:0-stifel-financial-corp-dep-rp-shs-pfd-cpr-declares-0-3828-dividend/
Stifel Financial Corp. DEP RP SHS PFD Cpr (SF.PR.C) has declared a quarterly dividend of $0.3828 per share, resulting in a forward yield of 7.87%. The dividend is payable on December 15th to shareholders of record as of December 1st, with an ex-dividend date of December 1st. This information is provided by Seeking Alpha for informational purposes.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement